Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | PTPRB | P23467 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | THRA | P10827 | 3/20 | 0.49 |
| ▸ | THRB | P10828 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.44 |
| ▸ | OGG1 | O15527 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15412587 | 0.87 | OGG1 (0.43) | MCL1HPGDPTPRBHSD17B10THRA | |
| SCHEMBL19766447 | 0.85 | HSD17B10 (0.55) | MCL1HPGDPTPRBHSD17B10THRA | |
| SCHEMBL14356223 | 0.84 | PTGS2 (0.46) | HPGDPTPRBHSD17B10ALDH1A1OGG1 | |
| SCHEMBL2276990 | 0.83 | MCL1 (0.56) | MCL1HPGDALDH1A1TSHR | |
| SCHEMBL7285425 | 0.81 | PTGDR2 (0.43) | MCL1TDP1TSHR | |
| SCHEMBL5531603 | 0.79 | MCL1 (0.69) | MCL1HPGDPTPRBHSD17B10THRA | |
| SCHEMBL13603769 | 0.78 | HPGD (0.69) | MCL1HPGDPTPRBHSD17B10THRA | |
| SCHEMBL14958764 | 0.78 | TSHR (0.44) | MCL1HPGDALDH1A1OGG1ALOX15 | |
| SCHEMBL15413021 | 0.78 | LMNA (0.47) | HPGDHSD17B10ALDH1A1LMNAKDM4E | |
| SCHEMBL6516217 | 0.77 | HPGD (0.62) | MCL1HPGDPTPRBHSD17B10THRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10682419-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20180147291-A1 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2018-05-31 | — | — | US | disclosed |
| US-9878047-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160263234-A1 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2016-09-15 | — | — | US | disclosed |
| US-9315542-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9309283-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| EP-2869820-A2 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | Onyx Therapeutics, Inc. (US) | 2015-05-13 | — | — | EP | disclosed |
| US-20140105921-A1 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors | ONYX THERAPEUTICS, INC. | 2014-04-17 | — | — | US | disclosed |
| US-20140100168-A1 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors | ONYX THERAPEUTICS, INC. | 2014-04-10 | — | — | US | disclosed |
| US-20140100154-A1 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors | ONYX THERAPEUTICS, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-7294716-B2 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | ALLERGAN, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| EP-1556371-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR | WINSTON PHARMACEUTICALS LLC (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1644352-A1 | PROCESS FOR PREPARING ISOMERICALLY PURE PRODRUGS OF PROTON PUMP INHIBITORS | Allergan, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050182101-A1 | Prodrugs of proton pump inhibitors | GARST MICHAEL (US) | 2005-08-18 | — | — | US | disclosed |
| EP-1556371-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR | Winston Pharmaceuticals LLC (US) | 2005-07-27 | — | — | EP | disclosed |
| US-6897227-B2 | Prodrugs of proton pump inhibitors | Winston Pharmaceuticals, Inc. (US) | 2005-05-24 | — | — | US | disclosed |
| WO-2005016917-A1 | PROCESS FOR PREPARING ISOMERICALLY PURE PRODRUGS OF PROTON PUMP INHIBITORS | ALLERGAN, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050038076-A1 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | ALEVIUM PHARMACEUTICALS, INC. | 2005-02-17 | — | — | US | disclosed |
| US-20040102484-A1 | Prodrugs of proton pump inhibitors | ALEVIUM PHARMACEUTICALS, INC. | 2004-05-27 | — | — | US | disclosed |
| WO-2004009583-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR | GARST MICHAEL E (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102484-A1 | Prodrugs of proton pump inhibitors | ABCB11, SLC10A2, SI | MCL1 2795/4885HPGD 127/4885PTPRB 1281/4885 |
| US-20140105921-A1 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors | PREP, VIP, PEPD | MCL1 2071/4885HPGD 344/4885PTPRB 3447/4885 |
| US-20140100168-A1 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors | PREP, VIP, PEPD | MCL1 2071/4885HPGD 344/4885PTPRB 3447/4885 |
| US-20160263234-A1 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, VIP, PEPD | MCL1 2071/4885HPGD 344/4885PTPRB 3447/4885 |
| US-20180147291-A1 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, VIP, PEPD | MCL1 2071/4885HPGD 344/4885PTPRB 3447/4885 |
| US-20140100154-A1 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors | PREP, VIP, PEPD | MCL1 2071/4885HPGD 344/4885PTPRB 3447/4885 |
| US-10682419-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | PREP, VIP, PEPD | MCL1 2071/4885HPGD 344/4885PTPRB 3447/4885 |
| US-20050038076-A1 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | SI, ATP6AP1, HRH2 | MCL1 1479/4885HPGD 19/4885PTPRB 3484/4885 |
| US-20050182101-A1 | Prodrugs of proton pump inhibitors | ABCB11, SLC10A2, SI | MCL1 3190/4885HPGD 118/4885PTPRB 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.